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Recent evidence has shifted the paradigm of white adipose tissue from simple energy storage to the body’s major endocrine 
and paracrine organ synthesizing and releasing multiple signaling proteins, collectively termed adipokines. White adipose tis-
sue is distributed in two large depots (subcutaneous and visceral) and many small depots associated with the heart, blood 
vessels, lymph nodes, ovaries, mammary glands, prostate gland, pancreas. Even in a lean person, adipose tissue represents 
about 15-20 % of body weight, including external (subcutaneous and visceral) and internal (organ-associated) adipose tissue, 
the latter being even more important than the former; however the internal fat distribution was beyond the scope of the pres-
ent study. nonalcoholic fatty liver disease (naFlD) is a term used to describe the accumulation of fat in the liver of people in the 
absence of alcohol consumption or consumption of less than 20g/day. It is a progressive, low-grade inflammatory disease rela-
ted to obesity and metabolic syndrome. naFlD represent a spectrum of disorders ranging from fat accumulation (steatosis) to 
nonalcoholic steatohepatitis (nash) that can progress to fibrosis and cirrhosis. The aim of the present study was to evaluate the 
clinic and metabolic parameters in patients with type 2 diabetes and naFlD depending on gender and bmI and to assess rela-
tion of adipose tissue distribution with insulin resistance. Total of 118 patients (mean age 55.93 years; male, 46, female, 72) with 
type 2 diabetes  evaluated in an outpatient diabetes clinic were diagnosed with naFlD by ultrasonography and were assessed 
by weight, body mass index (bmI), waist circumference, fasting plasma glucose, hbalc, and fasting insulin level.  We calculated 
the hOma-IR index [Fpg (mmol/l) x FI (μu/ml)]:22.5. body adipose percentage and trunk adipose content were measured using 
bioelectrical impedance analysis (TanITa bc-418). Overall, the present results suggest that insulin resistance may be considered 
a pathogenic link between T2Dm and naFlD, also at the level of adipose tissue distribution. Evaluating the distribution of inter-
nal, organ-associated adipose tissue remains a challenge for future studies in patients with T2Dm and naFlD.
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introduction 
Over the past 20-25 years, obesity and related diseases are among 
the major physical, social and economic burdens worldwide (1). 
The World Health Organization  has predicted a “globesity epi-
demic” with more than one billion adults being overweight (BMI 
over 25 kg/m2) and at least 400 million of these being clinically 
obese (BMI over 30 kg/m2). Arguably, we have learned more 
about the presence, distribution and function of adipose tissue. 
Also about the molecular control of food intake and energy ho-
meostasis, particularly, the role played by adipose tissue in the 
pathogenesis of cardiometabolic, malignant, neurodegenerative 
and liver (2,3) diseases. 
Even in a lean person, adipose tissue represents about 15-20 
% of body weight, including external (subcutaneous and vis-
ceral) and internal (organ-associated) adipose tissue, the latter 
being even more important than the former (4). Even along the 
same organ, for example, the aorta, the composition of the adi-
pose tissue surrounding the thoracic and abdominal parts of the 
aorta differs; the more abdominal part is surrounded by white 
adipose tissue, which is subject to obesity-related inflammation, 
whereas the thoracic part is surrounded by brown adipose tissue 
(Nicholas Hatch, 2012, Research Gate, comment).
     In humans, adipose tissue (hereafter to be considered white 
adipose tissue) is partitioned into two large depots (subcutane-
ous and visceral) and many small depots associated with heart, 
blood vessels, major lymph nodes, pancreas, prostate gland, 
mammary glands, ovaries, thymus. Noteworthy, upper-body 
adipose distribution is associated with complications of obesity 
while lower-body adipose distribution is protective though the 
mechanisms that govern regional adipose accumulation (5, also 
see these latter authors in this issue of Adipobiology).
Nonalcoholic fatty liver disease (NAFLD) is a term used to 
describe the accumulation of fat in the liver of people in the ab-
sence of alcohol consumption or consumption of less than 20g/
day. NAFLD represent a spectrum of disorders ranging from ste-
atosis to nonalcoholic steatohepatitis (NASH), fibrosis and cir-
rhosis. It is a progressive, low-grade inflammatory disease char-
acterized by fatty infiltration and association with obesity and 
metabolic syndrome. Patients with NAFLD may even respond to 
therapy (and weight loss) originally developed for other insulin-
resistant states. Many studies have demonstrated a link between 
NAFLD and insulin sensitivity, but the association with obesity 
and type 2 diabetes mellitus (T2DM) is a continuing subject of 
debate because not all obese individuals with diabetes present 
NAFLD, and not all patients with NAFLD are overweight or in-
sulin resistant. Increasing age, obesity and diabetes are consid-
ered independent predictors for the progression to nonalcoholic 
steatohepatitis (NASH) and fibrosis (6-15). Many epidemiologi-
cal studies have established a strong correlation between body 
mass index (BMI) and the presence of fatty liver diagnosed by 
ultrasonography.  Of patients diagnosed with NAFLD, 30–100% 
are obese (9), and 76% of obese patients have NAFLD, compared 
to 16% of normal weight individuals (10).  In overweight and 
obese patients with abnormal liver test results, liver biopsies re-
vealed septal fibrosis and cirrhosis in 30% and 10% of cases, re-
spectively.  In order to evaluate the risk of developing fibrosis, a 
score was calculated using the following combined values: BMI, 
age, alanine aminotransferase (ALT) and triglyceride levels (11). 
A predictive value for progression to fibrosis was assigned to a 
quantitative index of insulin resistance (Homeostasis Model As-
sessment for Insulin Resistance - HOMA-IR) in severely obese 
patients (14).
Studies that used liver histology to identify the presence 
of NAFLD have shown that some patients with NAFLD have 
normal weight and normal waist circumference.  Using waist 
circumference as a surrogate marker of visceral adiposity, 431 
patients with NAFLD diagnosed via liver biopsy were analyzed. 
Increasing visceral obesity was correlated with older age, a high-
er prevalence among females, altered glucose metabolism, hy-
pertension and metabolic syndrome. The progression to NASH 
and the presence of fibrosis were not associated with visceral 
adiposity.  Higher ALT levels and HOMA-IR more than 4 were 
associated with NASH independent of the presence of visceral 
adiposity (12).
The aim of the present study was to evaluate the clinic and 
metabolic parameters in patients with T2DM and NAFLD de-
pending on gender and BMI and to assess relation of adipose 
tissue distribution with insulin resistance.
patients and methods
A total of 118 patients (mean age 55.93 years; M/W, 46/72) 
with T2DM  evaluated in an outpatient diabetes clinic were 
diagnosed with NAFLD by ultrasonography and were assessed 
by height, weight, body mass index (BMI, kg/m2), waist cir-
cumference (WC, cm), fasting plasma glucose (FPG, mg/dl), 
HbAlc (%), and fasting insulin (FI, μU/ml).  We calculated the 
HOMA-IR index [FPG (mmol/l) x FI (μU/ml)]:22.5.  Body fat 
percentage and trunk fat content were measured using bio-
electrical impedance analysis (TANITA BC-418). Exclusion 
criteria: positive serologic markers for viral hepatitis and al-
cohol consumption > 20g/day. The statistical analysis program 
used was SPSS 15.0, with a statistical significance of p≤0.05*, 
p<0.001**.
results
 We observed a high prevalence of females versus males: 72 
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(61.01%) versus 46 (38.98%).  According to BMI values, we de-
fined two groups: group 1 consisted of 30 patients with a BMI > 
25 kg/m2 and < 30 kg/m2, and group 2 included 88 patients with 
a BMI ≥30 kg/m2. Of the patients studied, 25.42% were over-
weight and 74.57% were obese. Clinical and biochemical vari-
ables of studied patients organized by gender distribution and 
BMI values are listed in Table 1. 
Anthropometric and metabolic parameters were analyzed 
between overweight and obese patients for women and for men 
(Table 2). 
In the female group, fasting insulin (FI) levels and HOMA-













age (years) 56.13±9.42 55.73±7.86 ns 57.06±9.03 55.48±8.27 ns
Weight (kg) 95.00±11.19 85.22±13.65 ns 75.79±10.03 93.55±11.54 **
bmI (kg/m2) 31.49±3.72 33.57±4.98 * 27.41±1.35 34.58±3.86 **
Wc (cm) 109.43±9.2 107.19±10.39 ns 98.48±6.83 111.01±8.90 **
Fpg (mg/dl) 139.66±35.95 155.12±47.53 ns 139.57±37.16 152.63±45.84 ns
hba1c (%) 6.65±1.16 7.22±1.48 * 6.92±1.42 7.03±1.39 ns
Fasting insulin (FI) (µu/ml) 10.77±5.03 16.16±9.02 * 10.89±5.75 15.14±8.59 *
hOma-IR
index
3.81±2.08 6.21±4.01 * 4.01±2.77 5.75±3.78 *
body adipose tissue 
percent  (%)
28.73±5.87 42.33±4.91 ** 31.80±8.55 38.81±7.76 **
body adipose mass (kg) 27.66+7.85 36.55+9.28 ** 23.64±5.40 36.30±8.75 **
Trunk adipose tissue  
percent (%)
31.09±6.27 38.81±6.38 ** 30.98±7.72 37.49±6.48 **
Trunk adipose tissue mass 
(kg)
14.37±4.72 16.00±4.15 ns 11.08±3.43 17.05±3.49 **
* mean values for bmI, hba1c, FI and hOma-IR were significantly higher in the female versus male group.  In obese versus 
overweight patients, we found significantly higher values for: waist circumference, FI and hOma-IR.  body adipose tissue 
percentage, body adipose mass and trunk adipose tissue percentage were significantly higher in females vs. males, and, as we 
expected, in obese versus overweight patients.
IR were significantly higher in obese versus overweight patients. 
No statistically significant differences were observed in the male 
group with respect to BMI analysis. Body and trunk adipose per-
centage and mass were significantly higher in both females and 
males when compared obese versus overweight patients. Body 
adipose percentage and body adipose mass were correlated with 
waist circumference (p=0.0001), FI (p=0.001) and HOMA-IR 
(p=0.006).  The percentage of trunk adipose tissue was corre-
lated with waist circumference (p=0.0001), FI (p=0.01) and HO-
MA-IR (p=0.01).  No correlation was obtained for HbAlc with 
body and trunk adipose tissue.
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Discussion
In this study we evaluated the anthropometric and metabolic 
parameters in T2DM patients with NAFLD according to sex 
and BMI values.  Obesity is a common risk factor for fatty liver, 
and almost all patients with fatty liver have excess adipose tissue. 
Our results demonstrate that a significant percent of these pa-
tients, 61.01% are obese and 38.98% are overweight.  BMI values 
were significantly higher in the female group, which also had 
significantly higher HbA1c levels.
Many studies have demonstrated that patients with T2DM 
and fatty liver have a higher degree of insulin resistance than 
those with diabetes but without fatty liver, and T2DM patients 
have a greater amount of liver fat than nondiabetic patients (6-













Age (years) 56.57±10.21 55.93±9.21 ns 57.50±8.18 55.23±7.76 ns
Weight (kg) 84.18±6.81 99.74±9.30 ** 68.45±5.57 90.01±11.26 **
BMI (kg/m2) 27.49±1.38 33.24±2.98 ** 27.33±1.37 35.35±4.12 **
Waist 
circumference (cm)
99.80±7.61 112.75±7.19 ** 97.60±6.38 110.01±9.66 **
FPG (mg/dl) 127.20±20.88 145.48±40.14 * 150.39±44.99 156.47±48.53 ns
HbA1c (%) 6.30±0.82 6.83±1.28 ns 7.54±1.63 7.13±1.45 ns
Fasting insulin  
(µU/ml)
11.57±6.29 10.44±4.56 ns 10.12±5.46 17.08±9.14 *
HOMA-IR
index
3.84±2.57 3.79±1.91 ns 4.20±3.18 6.52±4.06 *
Body adipose 
tissue percent (%)
24.68±6.46 30.50±4.68 ** 38.03±4.05 43.55±4.45 **
Body adipose mass 
(kg)
20.91±6.09 30.62±6.66 ** 26.03±3.37 39.55±8.17 **
Trunk adipose 
tissue  percent (%)
26.16±6.78 33.16±4.80 ** 34.90±6.16 39.97±6.02 *
Trunk adipose 
tissue mass
9.46±4.63 16.21±3.41 * 11.77±2.95 17.35±3.55 *
15). In patients with NAFLD and without visceral obesity, liver 
disease can progress to steatohepatitis and fibrosis even if they 
have less metabolic disorders (14). Because adipose tissue is rec-
ognized as an active endocrine organ secreting multiple sign-
aling proteins (adipokines), an increase in total body fat mass 
can augment the production of pro-inflammatory adipokines, 
which, in turn, can promote pathogenic mechanisms of steato-
hepatitis (15). In our study, we observed a higher level of FI and 
a more advanced insulin resistant state in the female group as 
compared to the male group.  Also, as a primary indication in 
patients with NAFLD, gradual weight reduction must be evalu-
ated via body fat percentage and body fat mass needs to be mon-
itored. 
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Conclusions
From the present data, the following conclusions may be ex-
tracted: (i) the analysis of the patients studied according to 
gender revealed higher values for BMI, HbA1c, FI, HOMA-IR, 
body adipose tissue percentage, body adipose mass, and trunk 
adipose percentage in the female group, (ii) in the group with 
BMI ≥ 30, we observed higher values for FI and HOMA-IR in 
females but not males; as expected, the body and trunk adipose 
tissue percentages as well as body fat mass and trunk fat mass 
were higher in obese patients, and (iii) FI and HOMA-IR had a 
significant positive correlation with waist circumference, BMI 
and total body fat percentage.  A slightly positive correlation was 
found between FI, HOMA-IR and trunk adiposity. 
Overall, the present results suggest that insulin resistance 
may be considered a pathogenic link between T2DM and 
NAFLD, also at the level of adipose tissue distribution. Evaluat-
ing the distribution of internal, organ-associated adipose tissue 
(4) remains a challenge for future studies in patients with T2DM 
and NAFLD.
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